GW Pharma announce Darren Cline as company’s new Chief Commercial Officer

pharmafile | April 12, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

GW Pharmaceuticals have announced the appointment of Darren Cline as the company’s new US Chief Commercial Officer. Cline will lead the commercialisation of cannabidiol (CBD) based epilepsy medication Epidiolex in the United States.

Cline will succeed Julian Gangolli who announced he would be stepping down from his current role as President of GW Pharma’s US subsidiary, Greenwich Biosciences, in November 2018.

Cline is expected to start in his new role on 22 April 2019. Cline will however work with Gangolli for several weeks as he transitions into the organisation.

Cline brings to the role more than 25 years’ worth of commercial experience having previously taken on roles of increasing seniority at Washington-based biotech, Seattle Genetics, between 2010 and 2019.

Having graduated from San Diego University Cline joined California’s largest exporterr of wines, E. & J. Gallo Winery as a sales rep in 1989. Cline later took on a sales rep position at Schering-Plough, before taking on a series of senior marketing positions in pharmaceutical companies across the United States. Prior to joining Seattle Genetics, Cline took on senior roles at Amgen, InterMune and Alexion.

“We are delighted to have an executive of such high calibre as Darren Cline join our team as the new U.S. Chief Commercial Officer at GW. Darren brings significant commercial experience and a proven track record in execution which will help GW maximize the commercial opportunity of Epidiolex in the US,” Justin Gover, GW’s Chief Executive Officer (CEO), said.

“I also want to offer our deepest thanks to Julian Gangolli for his expert leadership in building a world-class U.S. commercial organization from scratch and shepherding Epidiolex through a successful launch. We wish him well in his retirement.”

Commenting on his own appointment, Cline said: “I am very excited to join GW and to lead such a talented U.S. commercial team. Epidiolex is an important new treatment that offers hope to many patients with Lennox-Gastaut Syndrome and Dravet syndrome who are in desperate need of new treatments to reduce their seizures. I look forward to continuing to deliver on GW’s mission of bringing transformational medicines to patients and building on the successful commercial organization in place to maximize the Epidiolex opportunity.”

Related Content

No items found

Latest content